INNOVUS PHARMACEUTICALS, INC. - FORM 10-Q - EX-32.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 - August 14, 2014

Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - INNOVUS PHARMACEUTICALS, INC.Financial_Report.xls
EX-31.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002. - INNOVUS PHARMACEUTICALS, INC.ex31-1.htm
EX-31.2 - CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002. - INNOVUS PHARMACEUTICALS, INC.ex31-2.htm
EX-10.8 - 8% DEBENTURE BETWEEN THE COMPANY AND DR. HENRY ESBER, PH.D., DATED MAY 30, 2014. - INNOVUS PHARMACEUTICALS, INC.ex10-2.htm
EX-10.9 - 8% DEBENTURE BETWEEN THE COMPANY AND LYNNETTE DILLEN, DATED JUNE 17, 2014. - INNOVUS PHARMACEUTICALS, INC.ex10-3.htm
10-Q - FORM 10-Q - INNOVUS PHARMACEUTICALS, INC.innv10qjune302014.htm
EX-32.2 - CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 - INNOVUS PHARMACEUTICALS, INC.ex32-2.htm
EXHIBIT 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report on Form 10-Q of Innovus Pharmaceuticals, Inc. (the “Corporation”) for the quarter ended June 30, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Bassam Damaj, principal executive officer of the Corporation, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
 
 
(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and
 
 
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Corporation as of June 30, 2014.
 
Dated: August 14, 2014
  
 /s/ Bassam Damaj
   
Bassam Damaj, President and Chief Executive Officer
(Principal Executive Officer)
 
“This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Corporation under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.”

INNOVUS PHARMACEUTICALS, INC. Reports